Expertise in
9
conditions

Dr. Jeremy P. Feldman

Bend Memorial Clinic PC
Bend, OR
Expertise in
9
conditions
Specialties:Pulmonary Medicine | Intensive Care Medicine
Accepting New Patients
Offers Telehealth
Expertise in
9
conditions
OverviewInsuranceLocationsClinical Research

Overview

Jeremy Feldman is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Bend, Oregon. Dr. Feldman is highly rated in 9 conditions, according to our data. His top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Pulmonary Fibrosis, Gastrostomy, and Splenectomy. Dr. Feldman is currently accepting new patients.

His clinical research consists of co-authoring 52 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pulmonary Medicine
Intensive Care Medicine
Licenses
Critical Care Medicine in AZ
Hospital Affiliations
St Charles Medical Center Prineville
St Charles Medical Center - Bend
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  BridgeSpan
  •  Cigna
  •  Medica
  •  Moda Health
  •  Regence
  •  Prominence Health
View 1 More Insurance +

Locations

BEND MEMORIAL CLINIC PC
1501 Ne Medical Ctr Dr, Bend, OR 97701
541-382-2811
Other Locations
ARIZONA PULMONARY SPECIALISTS LTD
9060 E Via Linda, Suite 250, Scottsdale, AZ 85258
602-261-7830

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety and Tolerability of Liposomal Treprostinil Inhalation Suspension (L606) in Subjects With Pulmonary Arterial Hypertension or Pulmonary Hypertension Associated With Interstitial Lung Disease
A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety and Tolerability of Liposomal Treprostinil Inhalation Suspension (L606) in Subjects With Pulmonary Arterial Hypertension or Pulmonary Hypertension Associated With Interstitial Lung Disease
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2024
Intervention Type: Combination product
Study Drug: L606
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Biological
Study Drug: Sotatercept
Study Phase: Phase 3
IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients With Pulmonary Arterial Hypertension (PAH)
IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients With Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Terminated
Publish Date: August 23, 2024
Intervention Type: Drug
Study Drug: AV-101
Study Phase: Phase 2/Phase 3
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: February 06, 2024
Intervention Type: Drug
Study Phase: Phase 3
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: February 06, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Completed
Publish Date: February 05, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension
A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: October 05, 2023
Intervention Type: Drug
Study Drug: Rodatristat Ethyl
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD
Enrollment Status: Terminated
Publish Date: July 27, 2023
Intervention Type: Combination product
Study Drug: INOpulse
Study Phase: Phase 3
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Completed
Publish Date: April 19, 2023
Intervention Type: Drug, Other
Study Drug: Sotatercept
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Enrollment Status: Completed
Publish Date: June 02, 2022
Intervention Type: Drug
Study Drug: UT-15C
Study Phase: Phase 3
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
Enrollment Status: Completed
Publish Date: February 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 11 Less Clinical Trials

52 Total Publications

Safety and efficacy of rodatristat ethyl for the treatment of pulmonary arterial hypertension (ELEVATE-2): a dose-ranging, randomised, multicentre, phase 2b trial.
Safety and efficacy of rodatristat ethyl for the treatment of pulmonary arterial hypertension (ELEVATE-2): a dose-ranging, randomised, multicentre, phase 2b trial.
Journal: The Lancet. Respiratory medicine
Published: March 28, 2024
Similar Doctors
Expertise in
9
conditions
Dr. Kevin E. Sherer
Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine
Expertise in
9
conditions
Dr. Kevin E. Sherer
Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine

Bend Memorial Clinic PC

1501 Ne Medical Ctr Dr, 
Bend, OR 
541-382-2811
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kevin Sherer is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Bend, Oregon. Dr. Sherer is highly rated in 9 conditions, according to our data. His top areas of expertise are Lung Metastases, Pulmonary Fibrosis, Pneumonia, and Acute Interstitial Pneumonia. Dr. Sherer is currently accepting new patients.

Expertise in
1
conditions
Dr. David J. Steiger
Intensive Care Medicine
Expertise in
1
conditions
Dr. David J. Steiger
Intensive Care Medicine

St Charles Health System Inc

2500 Ne Neff Rd, 
Bend, OR 
 (0.1 mi)
541-706-2768
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Steiger is an Intensive Care Medicine provider in Bend, Oregon. Dr. Steiger is highly rated in 1 condition, according to our data. His top areas of expertise are Venous Thromboembolism (VTE), Emphysema, Pulmonary Fibrosis, Embolectomy, and Gastrostomy. Dr. Steiger is currently accepting new patients.

Expertise in
21
conditions
Dr. Juan A. Tamariz-Loor
Pulmonary Medicine | Intensive Care Medicine
Expertise in
21
conditions
Dr. Juan A. Tamariz-Loor
Pulmonary Medicine | Intensive Care Medicine

St Charles Health System Inc

211 Nw Larch Ave, Family Care, 
Redmond, OR 
 (16.3 mi)
541-548-2164
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Juan Tamariz-Loor is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Redmond, Oregon. Dr. Tamariz-Loor is highly rated in 21 conditions, according to our data. His top areas of expertise are Lung Metastases, Pneumonia, Acute Interstitial Pneumonia, Lung Nodules, and Gastrostomy. Dr. Tamariz-Loor is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile